Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Inflammatory Bowel Diseases

Free Subscription 24.11.2025 3 Aliment Pharmacol Ther 2 Am J Gastroenterol 2 BMC Gastroenterol 2 Clin Gastroenterol Hepatol 2 Dig Dis Sci 4 Gastroenterology 16 Inflamm Bowel Dis 1 J Clin Gastroenterol 6 J Crohns Colitis 5 Lancet Gastroenterol Hepatol 2 Minerva Gastroenterol (Torino) 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. SINGH AK, Soni RK, Jearth V, Yadav AI, et al
   Clinical Trial: Immunogenicity of Double-Dose Versus Standard-Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease.
   Aliment Pharmacol Ther. 2025 Nov 20. doi: 10.1111/apt.70470.
   PubMed         Abstract available
   
   
2. LEE JD, Papamichael K, Grinspan LT, Cheifetz AS, et al
   Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease-Authors' Reply.
   Aliment Pharmacol Ther. 2025 Nov 17. doi: 10.1111/apt.70467.
   PubMed        
   
   
3. CHUNG Y, Nayagam JS
   Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease.
   Aliment Pharmacol Ther. 2025 Nov 17. doi: 10.1111/apt.70444.
   PubMed        
   
   

   
   Am J Gastroenterol

4. STIDHAM RW, Cai L, Wittrup E, Rice M, et al
   Artificial Intelligence Analysis of Endoscopy Outperforms Conventional Endoscopic Scoring for Agreement with Symptoms and Quality of Life in a Phase 3 Ulcerative Colitis Trial.
   Am J Gastroenterol. 2025 Nov 17. doi: 10.14309/ajg.0000000000003838.
   PubMed         Abstract available
   
   
5. TARIQ R
   Redefining Success in Inflammatory Bowel Disease Beyond Inflammation: Time to Aim Higher!
   Am J Gastroenterol. 2025 Nov 14. doi: 10.14309/ajg.0000000000003793.
   PubMed        
   
   

   
   BMC Gastroenterol

6. WANG KT, Su MI, Chiou WR, Chao CL, et al
   Impact of venous thromboembolism on mortality in hospitalized patients with inflammatory bowel disease: analysis of the MIMIC-IV database, 2008 to 2022.
   BMC Gastroenterol. 2025;25:825.
   PubMed        
   
   
7. KITAHATA S, Fukumoto M, Matsuoka K, Matsuda T, et al
   Factors associated with ulcerative colitis with non-anemic iron deficiency.
   BMC Gastroenterol. 2025;25:808.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

8. SUN J, Marild K, Bergman D, Ebrahimi F, et al
   Histologic remission and mortality in patients with inflammatory bowel disease: a nationwide cohort study.
   Clin Gastroenterol Hepatol. 2025 Nov 13:S1542-3565(25)00943.
   PubMed         Abstract available
   
   
9. VUYYURU SK, Hanzel J, Brar MS, Danese S, et al
   Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's Disease.
   Clin Gastroenterol Hepatol. 2025 Nov 18:S1542-3565(25)00988.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

10. MIYATANI Y, Choi D, Aronsohn AI, Pillai A, et al
    Safety and Efficacy of Upadacitinib in Patients with Inflammatory Bowel Disease After Liver Transplantation: A Case Series.
    Dig Dis Sci. 2025 Nov 20. doi: 10.1007/s10620-025-09569.
    PubMed         Abstract available
    
    
11. ZHONGCHENG L, Bo P, Dongting C, Kang C, et al
    Endoscopic Treatment for Crohn's Disease-Related Deep Small Intestinal Strictures: Balloon-Assisted Enteroscopy-Guided Stricturotomy Versus Balloon Dilation Therapy-A Single-Center Retrospective Study.
    Dig Dis Sci. 2025 Nov 14. doi: 10.1007/s10620-025-09529.
    PubMed         Abstract available
    
    

    
    Gastroenterology

12. BERNSTEIN CN, Gearry R, Nugent Z, Witt J, et al
    Global Discrepancies in Inflammatory Bowel Disease Care Reflect Health Care Expenditure Per Capita.
    Gastroenterology. 2025 Nov 14:S0016-5085(25)05902.
    PubMed        
    
    
13. SHANG A, Wang W, Zhao K
    Artificial Intelligence in Inflammatory Bowel Disease Management.
    Gastroenterology. 2025 Nov 15:S0016-5085(25)06035.
    PubMed        
    
    
14. GETTLER K, Nagpal S, Washburn S, Tastad C, et al
    Postoperative Ileum Transcriptomics Implicate Sex-Biased Mechanisms in Crohn's Disease Recurrence.
    Gastroenterology. 2025 Nov 18:S0016-5085(25)05983.
    PubMed         Abstract available
    
    
15. MARAFINI I, Salvatori S, Troncone E, Monteleone G, et al
    CD19 CAR T-Cell therapy for refractory ulcerative colitis.
    Gastroenterology. 2025 Nov 18:S0016-5085(25)06527.
    PubMed        
    
    

    
    Inflamm Bowel Dis

16. D'HOOGHE AT, Poulsen GJ, Sorensen CN, Tandon P, et al
    Unraveling Genetic Versus Environmental Factors Determining Disease Course in Inflammatory Bowel Diseases: A Population-Based Cohort Study in First- and Second-Generation Immigrants.
    Inflamm Bowel Dis. 2025;31:2955-2964.
    PubMed         Abstract available
    
    
17. LAW CCY, Sheskier R, Viera-Feliciano N, Delgado-Nieves A, et al
    Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion.
    Inflamm Bowel Dis. 2025;31:3077-3092.
    PubMed         Abstract available
    
    
18. ZITTAN E, Levy M, Vered S, Steinhart AH, et al
    Construct Validity of the Toronto IBD Global Endoscopic Reporting Score Compared to Inflammatory Biomarkers After 12-Month Follow-Up.
    Inflamm Bowel Dis. 2025;31:3120-3131.
    PubMed         Abstract available
    
    
19. TER AVEST MM, Huijbers MJ, Horjus CS, Romkens TEH, et al
    Group-Delivered Mindfulness-Based Cognitive Therapy to Reduce Psychological Distress and Improve Sleep in Patients With Inflammatory Bowel Diseases: A Multicenter Randomized Controlled Trial (MindIBD).
    Inflamm Bowel Dis. 2025;31:3021-3032.
    PubMed         Abstract available
    
    
20. TSE CS, Hunt MG, Lewis JD, Ostrov A, et al
    Preferences, Acceptability, and Utilization of Multimodal Self-Help Interventions in Adults With Inflammatory Bowel Diseases: A Pragmatic Multicenter Study With Patients and Clinicians.
    Inflamm Bowel Dis. 2025;31:3132-3141.
    PubMed         Abstract available
    
    
21. CAMARA H, Vicaut E, Caron B, Honap S, et al
    Bayesian Statistics: A Narrative Review on Application in Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2025;31:3183-3193.
    PubMed         Abstract available
    
    
22. CAO X, Zeng Z, Cao X, He Y, et al
    Generation and Phenotypic Analysis of the IL-10RAR104W/R104W Mouse Model.
    Inflamm Bowel Dis. 2025;31:3149-3159.
    PubMed         Abstract available
    
    
23. OLIVEIRA R, Roseira J
    Breaking Free from Corticosteroids in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Nov 13:izaf274. doi: 10.1093.
    PubMed         Abstract available
    
    
24. WANG D, Zhu D, Zhao X, Wang J, et al
    Fibroblast-Mediated MMP2 Contribution to Nonresponse in Anti-TNFalpha Therapy for Crohn's Disease.
    Inflamm Bowel Dis. 2025 Nov 14:izaf263. doi: 10.1093.
    PubMed         Abstract available
    
    
25. DALAL RS, Zeiss KE, Nielsen J, Madsen SD, et al
    Association of Spondyloarthritis With Chronic Opioid Use in Inflammatory Bowel Disease: A Nationwide Danish Cohort Study.
    Inflamm Bowel Dis. 2025 Nov 14:izaf281. doi: 10.1093.
    PubMed         Abstract available
    
    
26. JIMBO K, Arai N, Suzuki M, Suzuki E, et al
    Real-World Effectiveness of and Optimization Strategies for Mirikizumab in Pediatric Ulcerative Colitis: A Prospective, Observational Study.
    Inflamm Bowel Dis. 2025 Nov 18:izaf291. doi: 10.1093.
    PubMed         Abstract available
    
    
27. COMER-CALDER H, Morad HOJ
    The Paradox of NET Involvement in the Pathogenesis of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Nov 18:izaf283. doi: 10.1093.
    PubMed         Abstract available
    
    
28. LI L, Yuan X
    Early-Life Body Mass Index and Inflammatory Bowel Disease Risk: A Scandinavian Birth Cohort Study.
    Inflamm Bowel Dis. 2025 Nov 18:izaf260. doi: 10.1093.
    PubMed        
    
    
29. KURIAKOSE AC, Abraham D, Benny B, Govindan K, et al
    Exploring Gut Mucosal Microbiota to Distinguish Crohn's Disease from Intestinal Tuberculosis.
    Inflamm Bowel Dis. 2025 Nov 19:izaf285. doi: 10.1093.
    PubMed         Abstract available
    
    
30. BANIQUED MR, Greb AC, Shah ND, Parian AA, et al
    Nationwide Analysis of Food Insecurity among Individuals with Inflammatory Bowel Disease in the United States.
    Inflamm Bowel Dis. 2025 Nov 19:izaf289. doi: 10.1093.
    PubMed         Abstract available
    
    
31. GODDARD Q, Coward S, Seow CH, Bertazzon S, et al
    Association of Geography With Screening and Development of Cervical Neoplasia in Those With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Nov 20:izaf249. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

32. METSELAAR PI, van der Hoff MJ, van den Broek TJ, Kamstra RJM, et al
    Measuring Fatigue and Heart Rate Variability Using A Wearable Patch in Ulcerative Colitis Patients: A Cross-Sectional Pilot Study.
    J Clin Gastroenterol. 2025 Nov 14. doi: 10.1097/MCG.0000000000002286.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

33. SINGH S, Desai A, Goodwin S, Jairath V, et al
    Trends in utilization of advanced therapies in patients with inflammatory bowel diseases in the USA, 2021-2025.
    J Crohns Colitis. 2025;19:jjaf186.
    PubMed         Abstract available
    
    
34. LLAO J, Manosa M, Martin-Arranz E, Zabana Y, et al
    Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: A randomized, multicentre, open-label study by GETECCU.
    J Crohns Colitis. 2025 Nov 19:jjaf182. doi: 10.1093.
    PubMed         Abstract available
    
    
35. VENKAT S, Zeeman M, Hart A, Bhagat S, et al
    Serum Protein Profiles Differ with Adalimumab and Ustekinumab Treatment in Moderately to Severely Active Crohn's Disease.
    J Crohns Colitis. 2025 Nov 19:jjaf197. doi: 10.1093.
    PubMed         Abstract available
    
    
36. MOOJEN TB, Vlug MS, Visser E, Reijntjes MA, et al
    Modified-2-stage versus 3-stage approach in ileoanal pouch surgery for Ulcerative Colitis.
    J Crohns Colitis. 2025 Nov 19:jjaf201. doi: 10.1093.
    PubMed         Abstract available
    
    
37. IACUCCI M, Majumder S, Zammarchi I, Santacroce G, et al
    Automated real-time imaging of intestinal barrier integrity and molecular profiling for early outcome prediction in inflammatory bowel disease - Endo-Histo-Barrier-Omics study.
    J Crohns Colitis. 2025 Nov 19:jjaf200. doi: 10.1093.
    PubMed         Abstract available
    
    
38. VERMEIRE S, Colombel JF, Danese S, Panaccione R, et al
    Benefit-Risk Profile of Upadacitinib: Exploratory Post Hoc Analysis of Phase 2b/3 Studies in Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.
    J Crohns Colitis. 2025 Nov 20:jjaf198. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

39. VUIJK SA, Boute EH, de Ridder L
    Expanding the therapeutic arsenal for paediatric ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025 Nov 18:S2468-1253(25)00234.
    PubMed        
    
    
40. KAPLAN JL, Bousvaros A, Turner D, Dubinsky M, et al
    Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial.
    Lancet Gastroenterol Hepatol. 2025 Nov 18:S2468-1253(25)00196.
    PubMed         Abstract available
    
    
41. DE BOER NK, Gearry RB, Bernstein CN, Banerjee R, et al
    The essential medicines list for inflammatory bowel disease: time to raise the standards of global care.
    Lancet Gastroenterol Hepatol. 2025 Nov 17:S2468-1253(25)00299.
    PubMed        
    
    
42. JAIRATH V, Danese S, D'Haens GR, Feagan BG, et al
    Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.
    Lancet Gastroenterol Hepatol. 2025 Nov 13:S2468-1253(25)00296.
    PubMed         Abstract available
    
    
43. ATREYA R, Neurath MF
    Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025 Nov 13:S2468-1253(25)00330.
    PubMed        
    
    

    
    Minerva Gastroenterol (Torino)

44. CHEN ML, Nopsopon T, Papamichail K, Costenbader KH, et al
    Factors associated with the development of anti-drug antibodies to tumor necrosis factor-alpha inhibitors in patients with inflammatory bowel disease.
    Minerva Gastroenterol (Torino). 2025 Nov 20. doi: 10.23736/S2724-5985.25.03958.
    PubMed        
    
    
45. TROISI S, Sicilia G, Petito V, Masi L, et al
    The molecular basis of sarcopenia in inflammatory bowel disease: from gut-muscle axis to therapeutic opportunities.
    Minerva Gastroenterol (Torino). 2025 Nov 20. doi: 10.23736/S2724-5985.25.03967.
    PubMed         Abstract available
    
    

    
    PLoS One

46. QIN M, Liu X, Luo Q, Cai R, et al
    A multilayered genetic structure analysis between inflammatory bowel disease and bone density/osteoporosis.
    PLoS One. 2025;20:e0336775.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.